Title: Clinical analysis of interferon-alfa and adefovir sequential treatment for chronic hepatitis B
Abstract: Objective To evaluate the efficacy and safety of adefovir (ADV) in the treatment of chronic hepatitis B patients with no response to 12 weeks treatment of interferon-α. Methods After 12 weeks treatment of interferon-α, 36chronic hepatitis B patients with HBeAg positive or HBV DNA > 5log10 copies/mL were randomly assigned as treatment group and control group. 18 patients in treatment group were accepted ADV, and other 18 patients in control group continued to accept intefferon-α for 52 weeks. Results At the end of 52 weeks, HBV DNA levels in treatment group reduced obviously compared to control group( χ2 = 3.04, P < 0.01 ); the ratio of patients whose HBV DNA levels reduced above 2 log in treatment group was also obviously compared to control group( χ2 = 11.10, P < 0.01 ). In treatment group, the negative ratio of HBeAg was 22.22%, and the ratio of HBeAg seroconversion was 11. 11%, in control group both rates were 27.78% and 16.67% respectively, and there was no difference between the two groups. In treatment group, 88.89% of patients achieved ALT normalization, and in control group achieved 61.11% ( P <0.05). After 24weeks, the rebound rate of patients with HBV DNA < 5log10 copies/mL at the end of treatment was 25.00% in tteatment group, and 16.67% in control group. Conclusions ADV can restrain the repliication of HBV in patients who have no response to 12 weeks treatment of interferon-α, but its effect on HBeAg seroconversion is not obvious. ADV is safe in the 52 weeks of treatment, but the end of the treatment is remaining further study.
Key words:
Hepatitis B,ehronic; Interferon-α; Adefovir
Publication Year: 2010
Publication Date: 2010-08-25
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot